Evaluation of the efficacy of XELOX(L-OHP: 100mg/m2)+Bevacizumab for patient with metastatic or recurrent Colorectal Cancer as first-line chemotherapy

ABSTRACT: Interventions: Capecitabine plus oxaliplatin(L-OHP: 100mg/m2) with bevacizumab Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2623078 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR